Multimedia Library
Laparoscopic loop duodenaljejunal bypass with sleeve gastrectomy in type 2 diabetic patients
Diabetes is an epidemic disease and is estimated to affect >300 million people worldwide in 2025 [1]. Type 2 diabetes (T2D) management is a combination of diet, lifestyle modifications, and drug therapy. Recently, many studies have shown remission of T2D in obese population [2–6]. Buchwald et al. [2] in his systemic review and meta-analysis showed that diabetes remission rates were 99% (95% confidence interval, 97%–100%) after biliopancreatic diversion, 84% (95% confidence interval, 77%–90%) after Roux-en-Y gastric bypass (RYGB), and 48% (95% confidence interval, 29%–67%) after gastric banding.PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery
Obesity is the major trigger of nonalcoholic fatty liver disease (NAFLD). NAFLD is further favored by the patatin-like phospholipase domain-containing 3 (PNPLA3) p.I148M, transmembrane 6 superfamily member 2 (TM6SF2) p.E167K, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 variants.Trans-oral Endoscopic Restrictive Implant System: endoscopic treatment of obesity?
Endoscopic treatment of obesity might be an alternative to surgical treatment or, preoperatively, serve as an auxiliary therapy to surgery in patients at increased surgical risk.Hepatic abscess as a complication of duodenal-jejunal bypass sleeve system and review of the literature
The obesity epidemic is steadily increasing worldwide, and high body mass index (BMI) is a major risk factor for cardiovascular diseases, diabetes, hypertension, musculoskeletal disorders, and also some cancers [1]. Diets are generally unsuccessful [2]. Bariatric surgery is today the main treatment for severe obesity [3]. There is a strong interest in finding less invasive methods [4] and whether that preoperative weight loss improves surgery outcomes [2] and reduces perioperative complications [5].
